trial

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

NCTId NCT03351244
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 264 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2021-03-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
264 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-12-07
Primary completion
2021-03-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
BI 409306

Sponsors

Boehringer IngelheimLead Sponsor

Sites

59 total
Phoenix, United StatesCosta Mesa, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesLos Angeles, United StatesOceanside, United StatesOrange, United StatesTorrance, United StatesHallandale, United StatesHialeah, United StatesMaitland, United States

Linked catalysts

1
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Bec — primary completion2021-03-10

Facts & assertions

4 sourced
Enrollment
264
Phase
PHASE2
Primary Completion Date
2021-03-10
Status
TERMINATED
relationships
The graph out of here
drug
BI 409306
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication